1. Velseboer, DC, de Haan, RJ, Wieling, W, Goldstein, DS, de Bie, RMA. Prevalence of orthostatic hypotension in parkinson’s disease: a systematic review and meta-analysis. Park Relat Disord. 2011;17:724-729. DOI: 10.1016/j.parkreldis.2011.04.016.
Google Scholar | Crossref | Medline2. Freeman, R, Wieling, W, Axelrod, FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69-72. DOI: 10.1007/s10286-011-0119-5.
Google Scholar | Crossref | Medline | ISI3. Freeman, R, Abuzinadah, AR, Gibbons, C, Jones, P, Miglis, MG, Sinn, DI. Orthostatic hypotension. J Am Coll Cardiol. 2018;72:1294-1309. https://doi.org/https://doi.org/10.1016/j.jacc.2018.05.079
Google Scholar | Crossref | Medline4. Brignole, M, Moya, A, de Lange, FJ, et al. Practical instructions for the 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:e43-1948. DOI: 10.1093/eurheartj/ehy037.
Google Scholar | Crossref | Medline5. Udow, SJ, Robertson, AD, MacIntosh, BJ, et al. ‘Under pressure’: is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies? J Neurol Neurosurg Psychiatr. 2016;87(12):1311-1321. doi:10.1136/jnnp-2016-314123. Epub 2016 Sep 9. PMID: 27613160.
Google Scholar | Crossref | Medline6. Noack, C, Schroeder, C, Heusser, K, Lipp, A. Cardiovascular effects of levodopa in parkinson’s disease. Park Relat Disord. 2014;20:815-818. doi:10.1016/j.parkreldis.2014.04.007.
Google Scholar | Crossref | Medline7. Calne, DB, Brennan, J, Spiers, ASD, Stern, GM. Hypotension caused by L-dopa. Bmj. 1970;1:474-475. doi:10.1136/bmj.1.5694.474.
Google Scholar | Crossref | Medline8. Parkes, JD . Adverse effects of antiparkinsonian drugs. Drugs. 1981;21:341-353. doi:10.2165/00003495-198121050-00002.
Google Scholar | Crossref | Medline9. Milon, D, Allain, H, Reymann, J, Morel, G, Sabouraud, O, Driessche, J. Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians. Fund Clin Pharmacol. 1990;4:695-705. doi:10.1111/j.1472-8206.1990.tb00049.x.
Google Scholar | Crossref | Medline10. Schoenberger, JA . Drug-induced orthostatic hypotension. Drug Saf. 1991;6:402-407. doi:10.2165/00002018-199106060-00002.
Google Scholar | Crossref | Medline11. Heinonen, EH, Myllylä, V. Safety of selegiline (deprenyl) in the treatment of parkinson’s disease. Drug Saf. 1998;19:11-22. doi:10.2165/00002018-199819010-00002.
Google Scholar | Crossref | Medline12. Kulisevsky, J, Pagonabarraga, J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of parkinson’s disease. Drug Saf. 2010;33:147-161. doi:10.2165/11319860-000000000-00000.
Google Scholar | Crossref | Medline13. Freemantle, N, Marston, L, Walters, K, Wood, J, Reynolds, MR, Petersen, I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ (Clinical research ed.). 2013;347:f6409. doi:10.1136/bmj.f6409.
Google Scholar | Crossref | Medline14. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269. doi:10.7326/0003-4819-151-4-200908180-00135.
Google Scholar | Crossref | Medline | ISI15. York University . Prospero. 2020. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020168697 (accessed Apri 04, 21)
Google Scholar16. University of Oxford . EBM datalab, (n.d.). https://openprescribing.net/ (accessed November 28, 2020).
Google Scholar17. Ouzzani, M, Hammady, H, Fedorowicz, Z, Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi:10.1186/s13643-016-0384-4.
Google Scholar | Crossref | Medline18. Sterne, JAC, Savović, J, Page, MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
Google Scholar | Crossref | Medline19. Guyatt, GH, Oxman, AD, Vist, GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926. doi:10.1136/bmj.39489.470347.AD.
Google Scholar | Crossref | Medline20. Limousin, P, Pollak, P, Pfefen, JP, Tournier-Gervason, CL, Dubuis, R, Perret, JE. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, parkinson’s disease. Clin Neuropharmacol. 1995;18:258-265. https://journals.lww.com/clinicalneuropharm/Fulltext/1995/06000/Acute_Administration_of_Levodopa_Benserazide_and.6.aspx
Google Scholar | Crossref | Medline21. Olanow, CW, Kieburtz, K, Stern, M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable parkinson disease. Arch Neurol. 2004;61:1563-1568. doi:10.1001/archneur.61.10.1563.
Google Scholar | Crossref | Medline22. Takahashi, M, Yuasa, R, Yuasa, R, et al. Selegiline (L-Deprenyl) and L-dopa treatment of parkinson's disease: a double-blind trial. Intern Med. 1994;33:517-524. doi:10.2169/internalmedicine.33.517.
Google Scholar | Crossref | Medline23. Presthus, J, Hajba, A. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of parkinson’s disease. Acta Neurol Scand. 1983;68:127-133. doi:10.1111/j.1600-0404.1983.tb01527.x
Google Scholar | Crossref24. Brodersen, P, Philbert, A, Gulliksen, G, Stigård, A. The effect of L-deprenyl on on-off phenomena in parkinson’s disease. Acta Neurologica Scandinavica. 1985;71:494-497. doi:10.1111/j.1600-0404.1985.tb03233.x.
Google Scholar | Crossref | Medline25. Weintraub, D, Hauser, RA, Elm, JJ, Pagan, F, Davis, MD, Choudhry, A, for the M. Investigators, Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 31 (2016) 709–714. doi:10.1002/mds.26617
Google Scholar | Crossref | Medline26. Möller, JC, Oertel, WH, Köster, J, Pezzoli, G, Provinciali, L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial. Mov Disord. 2005;20:602-610. doi:10.1002/mds.20397.
Google Scholar | Crossref | Medline27. Hubble, JP, Koller, WC, Cutler, NR, et al. Pramipexole in patients with early parkinson’s disease. Clin Neuropharmacol. 1995;18:338-347. https://journals.lww.com/clinicalneuropharm/Fulltext/1995/08000/Pramipexole_in_Patients_with_Early_Parkinson_s.6.aspx
Google Scholar | Crossref | Medline | ISI28. Schapira, AH, McDermott, MP, Barone, P, et al. Pramipexole in patients with early parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12:747-755. doi:10.1016/S1474-4422(13)70117-0.
Google Scholar | Crossref | Medline29. Wermuth, L . A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced parkinson’s disease. Eur J Neurol. 1998;5:235-242. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=10210837
Google Scholar | Crossref | Medline30. Barone, P, Poewe, W, Albrecht, S, et al. Pramipexole for the treatment of depressive symptoms in patients with parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573-580. doi:10.1016/S1474-4422(10)70106-X.
Google Scholar | Crossref | Medline | ISI31. Nicholas, AP, Borgohain, R, Chaná, P, Surmann, E, Thompson, EL, Bauer, L, et al. A Randomized Study of Rotigotine Dose Response on 'Off' Time in Advanced Parkinson's Disease. J Parkinsons Dis. 2014;4:361-373. doi:10.3233/JPD-130320.
Google Scholar | Crossref | Medline32. Hutton, JT, Metman, LV, Chase, TN, et al. Transdermal dopaminergic D 2 receptor agonist therapy in parkinson’s disease with N‐0923 TDS: a double‐blind, placebo‐controlled study. Mov Disord. 2001;16:459-463. doi:10.1002/mds.1085.
Google Scholar | Crossref | Medline | ISI33. Gunzler, SA, Koudelka, C, Carlson, NE, Pavel, M, Nutt, JG. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol. 2008;65:193-198. doi:10.1001/archneurol.2007.58.
Google Scholar | Crossref | Medline34. Pahwa, R, Koller, WC, Trosch, RM, Sherry, JH. Subcutaneous apomorphine in patients with advanced parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007;258:137-143. doi:10.1016/j.jns.2007.03.013.
Google Scholar | Crossref | Medline35. Ondo, W, Hunter, C, Almaguer, M, Gancher, S, Jankovic, J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating parkinson’s disease. Clin Neuropharmacol. 1999;22:1-4. https://journals.lww.com/clinicalneuropharm/Fulltext/1999/01000/Efficacy_and_Tolerability_of_a_Novel_Sublingual.1.aspx
Google Scholar | Crossref | Medline36. Pahwa, R, Stacy, MA, Factor, SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced parkinson disease. Neurology. 2007;68:1108-1115. doi:10.1212/01.wnl.0000258660.74391.c1.
Google Scholar | Crossref | Medline | ISI37. Oertel, W, Eggert, K, Pahwa, R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in parkinson’s disease (EASE LID 3). Mov Disord. 2017;32:1701-1709. doi:10.1002/mds.27131.
Google Scholar | Crossref | Medline38. Hauser, RA, Isaacson, SH, Ellenbogen, A, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in parkinson’s disease. Park Relat Disord. 2019;64:175-180. doi:10.1016/j.parkreldis.2019.03.026.
Google Scholar | Crossref | Medline39. Hauser, RA, Hubble, JP, Truong, DD. Randomized trial of the adenosine A2Areceptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297-303. doi:10.1212/01.WNL.0000081227.84197.0B.
Google Scholar | Crossref | Medline40. Olanow, CW, Factor, SA, Espay, AJ, et al. Apomorphine sublingual film for off episodes in parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19:135-144. doi:10.1016/S1474-4422(19)30396-5.
Google Scholar | Crossref | Medline41. Trotti, A, Colevas, A, Setser, A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181. doi:10.1016/S1053-4296(03)00031-6.
Google Scholar | Crossref | Medline | ISI42. Parkinson’s UK . The incidence and prevalence of parkinson’s in the UK. 2018. https://www.parkinsons.org.uk/sites/default/files/2018-01/CS2960. Incidence and prevalence report branding summary report.pdf.
Google Scholar43. Herrera, AP, Snipes, SA, King, DW, Torres-Vigil, I, Goldberg, DS, Weinberg, AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Publ Health. 2010;100(Suppl l):S105-S112. doi:10.2105/AJPH.2009.162982.
Google Scholar | Crossref | Medline44. Zhou, C-Q, Zhang, J-W, Wang, M, Peng, G-G.